If you’ve been offered abiraterone or enzalutamide for prostate cancer, you may wonder why your specialist has recommended one over the other. Both treatments target male hormones to help slow cancer growth, but they work differently and have different side effects and treatment requirements.
You may also want to know whether you’ll need steroids, regular blood tests or changes to your daily routine. Neither medicine is right for everyone, so understanding the differences can help you discuss your options with your specialist and choose a treatment that suits your health needs.
What Are Abiraterone and Enzalutamide?
If your specialist has offered you abiraterone or enzalutamide, you may want to know how they work. Both help slow prostate cancer by targeting male hormones, but in different ways. Abiraterone reduces hormone production, while enzalutamide blocks these hormones from sending growth signals to cancer cells.
You usually take both as daily tablets, but there’s an important difference: abiraterone is normally taken with a steroid such as prednisolone, while enzalutamide usually doesn’t require one. Your specialist will consider your cancer and overall health when recommending a treatment.
Abiraterone vs Enzalutamide: Key Differences
| Feature | Abiraterone | Enzalutamide |
| How it works | Inhibits CYP17A1 and reduces androgen synthesis | Blocks the androgen receptor |
| ADT usually continues? | Yes | Yes |
| Steroid required? | Usually yes | Usually no |
| Food restrictions | Standard tablets must be taken fasting | Can be taken with or without food |
| Key monitoring | Liver function, potassium, BP, fluid retention | BP, fatigue, falls, cognition, neurological effects |
| Important side effects | Hypertension, low potassium, fluid retention, liver toxicity | Fatigue, hypertension, falls, fractures, cognitive effects |
How Does Abiraterone Work Against Prostate Cancer?
If you’re taking abiraterone, it works by reducing the production of testosterone and other hormones that can help prostate cancer grow. It blocks an enzyme called CYP17 and is usually given alongside hormone therapy (ADT), unless you’ve had surgery to remove your testicles.
Because this also affects other hormones, you may develop high blood pressure, low potassium or swelling. That’s why you’ll usually take prednisolone or prednisone alongside it and have regular checks of your liver function, potassium and blood pressure.
How Does Enzalutamide Work Differently?
If you’re taking enzalutamide, it works by blocking the receptors that allow male hormones to send growth signals to prostate cancer cells. Unlike abiraterone, it doesn’t mainly reduce testosterone production; it stops cancer cells from responding to these hormones.
You usually don’t need to take a steroid alongside enzalutamide. However, you may experience tiredness, dizziness, falls, high blood pressure or changes in memory and concentration. Your specialist will consider your health and any existing balance or memory problems when deciding if it’s suitable for you.
When Are Abiraterone and Enzalutamide Used?

You may be offered abiraterone or enzalutamide if your prostate cancer has spread or continues growing despite hormone treatment. Both are used in certain metastatic hormone-sensitive and castration-resistant settings. However, their non-metastatic uses differ: abiraterone is commissioned for selected high-risk hormone-sensitive cases in England, while enzalutamide has licensed non-metastatic indications, but NHS recommendations and funding differ according to the disease setting.
You may be eligible for one treatment but not the other, depending on your diagnosis, previous treatments and NHS criteria. Your specialist can explain which options are suitable for you and your stage of prostate cancer.
UK Guidance Note
In England, abiraterone plus prednisolone has been routinely commissioned since January 2026 for eligible adults with high-risk hormone-sensitive non-metastatic prostate cancer. This particular indication is off-label and follows specific NHS England eligibility criteria.
Enzalutamide has licensed non-metastatic uses, including selected high-risk castration-resistant disease and high-risk biochemical recurrence, but licensing does not automatically mean routine NHS funding. NICE TA580 did not recommend enzalutamide for high-risk non-metastatic hormone-relapsed prostate cancer, while a separate appraisal after prostatectomy or radiotherapy (TA994) was terminated. Your specialist will explain which indications and funding arrangements apply. These disease settings should not be treated as interchangeable.
Is Abiraterone or Enzalutamide More Effective?
You may wonder which medicine is more likely to control your prostate cancer. Both abiraterone and enzalutamide can delay cancer progression and improve survival in certain situations, but many studies didn’t compare them directly, so their results can’t always be compared fairly.
Your specialist will consider your cancer stage, previous treatments, scan results and overall health when discussing your options. A treatment that suits someone else may not be right for you, so it’s important to look at the evidence for your individual circumstances.
Research Insight
A 2026 systematic review and meta-analysis included 47 real-world observational studies and 71,984 patients with metastatic castration-resistant prostate cancer. Enzalutamide was associated with higher rates of a PSA reduction of at least 50% (PSA50) and better overall survival, but treatment discontinuation was also more frequent.
However, no randomised head-to-head trials were included, so these results cannot prove that enzalutamide is intrinsically more effective. Doctors may preferentially prescribe one medicine to healthier or higher-risk patients, creating important selection bias.
How Do You Take Abiraterone and Enzalutamide?
You usually take both medicines once a day, but the timing matters. Standard abiraterone tablets must be taken on an empty stomach, at least two hours after eating, with no food for at least one hour afterwards. Enzalutamide can be taken with or without food, giving you more flexibility.
Your prescribed dose and tablet number will depend on the strength supplied. Follow your prescription, and don’t crush or change your tablets without checking with your pharmacist or specialist. If you struggle with the instructions, ask your treatment team for help.
Why Does Abiraterone Need Prednisolone but Enzalutamide Usually Does Not?
If you’re taking abiraterone, you’ll usually need prednisolone or prednisone because the medicine reduces cortisol production and can increase ACTH-driven hormonal effects. These changes can cause fluid retention, high blood pressure and low potassium. The steroid helps reduce these risks.
Enzalutamide works differently by blocking hormone signals, so you don’t usually need a steroid alongside it. If you’re prescribed prednisolone, never stop taking it suddenly without speaking to your doctor.
What Are the Main Side Effects of Abiraterone?

If you’re taking abiraterone, you may experience high blood pressure, swollen ankles, weight gain or low potassium. You might also notice muscle weakness, cramps, palpitations, tiredness or digestive problems.
Abiraterone can also affect your liver, sometimes without obvious symptoms. That’s why you’ll need regular blood tests and blood pressure checks. Tell your treatment team about any unusual symptoms so they can help you manage them.
What Are the Main Side Effects of Enzalutamide?
If you’re taking enzalutamide, you may notice tiredness, dizziness, headaches or high blood pressure. You might also experience memory or concentration problems, which can make everyday activities more difficult.
Enzalutamide can also increase your risk of falls and fractures, while seizures are rare but serious. Tell your specialist about any existing balance problems or history of seizures so they can assess whether this treatment is suitable for you.
Which Medicine Is Better if You Have High Blood Pressure or Heart Problems?
If you have high blood pressure or heart problems, your specialist will consider these carefully before recommending treatment. Abiraterone can cause fluid retention, high blood pressure and low potassium, while enzalutamide can also raise blood pressure and may affect heart health.
Neither medicine is automatically safer for you. Your medical history and current medicines will help your specialist decide what may suit you, with regular monitoring. Tell your team about new swelling, palpitations or breathlessness, and seek emergency help for chest pain or sudden severe breathlessness.
Clinical Note
Both abiraterone and enzalutamide can affect cardiovascular health. Abiraterone may cause high blood pressure, low potassium and fluid retention, while enzalutamide can also raise blood pressure and may affect heart rhythm or circulation.
Your specialist will consider your heart health, blood pressure, potassium levels and other medicines before recommending treatment. Neither option is automatically safer for everyone.
How Do Liver Problems Affect Treatment Choice?
If you have liver problems, your specialist will assess you carefully before recommending abiraterone. It can affect liver function, so you’ll need regular blood tests, especially during the first few months. Severe liver impairment is a contraindication, while significant abnormalities during treatment may require a pause, dose adjustment or permanent discontinuation.
Enzalutamide is also processed by your liver, so existing liver disease still needs careful assessment. Tell your specialist if you have hepatitis, cirrhosis or abnormal liver tests so they can consider the safest option for you.
Which Treatment Requires More Blood Tests and Monitoring?

If you’re taking abiraterone, you’ll usually need more frequent safety blood tests, particularly during the first three months. Your team will check your liver function before treatment, every two weeks initially and monthly afterwards, alongside potassium, blood pressure and fluid retention monitoring.
With enzalutamide, your appointments will focus more on side effects such as tiredness, falls, memory changes and blood pressure. Both treatments require PSA checks and regular reviews to see how well your cancer is responding. Your team can help arrange monitoring around your needs.
Can Abiraterone and Enzalutamide Interact With Other Medicines?
If you take other medicines for your heart, blood pressure, diabetes or other conditions, tell your specialist before starting either treatment. Abiraterone can affect how some medicines work and may cause problems with potassium levels or heart rhythm. Enzalutamide can reduce the effectiveness of some medicines, including certain blood thinners, while other medicines, including some epilepsy treatments, can affect enzalutamide levels or its safety.
Remember to mention vitamins, supplements and herbal products too. St John’s wort can interact with both treatments. Don’t stop any prescribed medicine yourself; ask your specialist or pharmacist to check your medication list.
Can You Switch From Abiraterone to Enzalutamide or Vice Versa?
If you’re struggling with side effects or your treatment is no longer controlling your cancer, you may wonder whether switching medicines could help. Your specialist will consider your symptoms, health and previous treatments before recommending another option.
If your cancer progresses, switching directly between these medicines may provide limited benefit because resistance to one can reduce your response to the other. However, some patients still benefit, particularly from enzalutamide after abiraterone. Your specialist may discuss chemotherapy or other options. Never switch or combine treatments without medical advice.
Evidence Note
A randomised phase 2 crossover trial enrolled 202 men with metastatic castration-resistant prostate cancer who were starting one of these treatments. Abiraterone followed by enzalutamide produced a longer time to second PSA progression than the reverse sequence: 19.3 months versus 15.2 months.
After crossover, a PSA response occurred in 36% of patients receiving second-line enzalutamide compared with only 4% receiving second-line abiraterone.
How Do Specialists Decide Which Medicine Is Right for You?
There is no single treatment that suits everyone. Your specialist will consider several factors before recommending abiraterone or enzalutamide:
- Cancer setting: Hormone-sensitive, castration-resistant, metastatic and non-metastatic disease have different treatment options.
- Previous treatments: Previous ADT, chemotherapy or androgen-receptor pathway treatment can influence how well another medicine may work.
- Heart health: Abiraterone may need particular caution if you have heart failure, fluid retention or difficult-to-control blood pressure.
- Potassium levels: Recurrent low potassium can make abiraterone more complicated to manage.
- Liver health: Abiraterone requires more intensive liver monitoring and may be unsuitable with severe liver impairment.
- Falls and cognition: If you have balance problems, previous falls or memory difficulties, your specialist may consider these risks when assessing enzalutamide.
Your specialist should balance these factors against the likely cancer-control benefit and your own treatment priorities.
What Questions Should You Ask Before Starting Treatment?

Before starting abiraterone or enzalutamide, ask your specialist why they recommend it for you, what benefits you can expect and how to take it correctly. You may also want to know about fasting rules, prednisolone, possible side effects and how often you’ll need blood tests.
Make sure you know which symptoms need urgent attention, who to contact if you’re worried and what to do if you miss a dose. You can also ask how your response will be monitored and what other options are available if treatment stops working or becomes difficult to manage.
Myth vs Fact
| Myth | Fact |
| Abiraterone and enzalutamide work in the same way. | Both target androgen signalling, but abiraterone reduces androgen synthesis while enzalutamide blocks the androgen receptor. |
| Enzalutamide is always stronger. | Observational results may favour enzalutamide, but neither treatment is universally better for every patient. |
| Abiraterone always needs to be taken with food. | Standard tablets must be taken fasting. |
| Enzalutamide needs prednisolone too. | Routine steroid cover is generally required with abiraterone, not enzalutamide. |
| Only enzalutamide can be used before metastatic disease. | NHS England now commissions abiraterone for selected high-risk non-metastatic hormone-sensitive disease. |
Key Takeaways
- Abiraterone and enzalutamide both target the androgen pathway but work differently.
- Abiraterone inhibits CYP17A1 and reduces androgen production.
- Enzalutamide blocks the androgen receptor.
- ADT usually continues with either treatment.
- Abiraterone normally requires prednisone or prednisolone.
- Enzalutamide usually does not require corticosteroid cover.
- Standard abiraterone tablets must be taken fasting.
Frequently Asked Questions
1. What is the main difference between abiraterone and enzalutamide?
Abiraterone reduces the production of testosterone and other male hormones, while enzalutamide blocks cancer cells from responding to these hormones. Both help slow prostate cancer growth but work differently.
2. Which is more effective for prostate cancer: abiraterone or enzalutamide?
Both treatments can delay cancer progression and improve survival in certain situations. Your specialist will consider your cancer stage, previous treatments and overall health when recommending one.
3. Why do you need prednisolone with abiraterone but not usually with enzalutamide?
Abiraterone can cause high blood pressure, fluid retention and low potassium by changing your hormone balance. Prednisolone helps reduce these risks, while enzalutamide usually doesn’t require a steroid.
4. How do you take abiraterone and enzalutamide?
Abiraterone is usually taken on an empty stomach, at least two hours after food and one hour before eating again. Enzalutamide can be taken with or without food.
5. What are the common side effects of abiraterone?
Abiraterone can cause high blood pressure, swollen ankles, weight gain, low potassium, muscle weakness and tiredness. It can also affect your liver, so regular blood tests are important.
6. What are the common side effects of enzalutamide?
Common side effects include tiredness, dizziness, headaches and high blood pressure. You may also experience falls, fractures or changes in memory and concentration.
7. Which treatment is better if you have heart problems or high blood pressure?
Neither treatment is automatically safer if you have heart problems or high blood pressure. Your specialist will assess your medical history, current medicines and individual risks before recommending one.
8. Which treatment needs more blood tests and monitoring?
Abiraterone usually requires more frequent blood tests, particularly during the first three months, to check your liver function and potassium. Both treatments also require blood pressure monitoring, PSA checks and regular reviews.
9. Can you switch from abiraterone to enzalutamide if your cancer progresses?
Your specialist may consider switching, but changing directly between these medicines after cancer progression may offer limited benefit because they target the same hormone pathway. Other treatments, such as chemotherapy, may be discussed.
10. Can you take abiraterone and enzalutamide together?
Abiraterone and enzalutamide are not routinely recommended together. Clinical trials found no clear overall-survival advantage from combining them and reported more side effects. Your specialist will decide which treatment is appropriate for your cancer. Never combine or change these medicines without medical advice.
Final Thoughts: Choosing Between Abiraterone and Enzalutamide
Abiraterone and enzalutamide can both help control prostate cancer, but they work differently and have different side effects, monitoring requirements and daily instructions. Abiraterone is usually taken with prednisolone and requires regular checks of your liver function and potassium, while enzalutamide may cause tiredness, dizziness, falls and changes in concentration. The right option depends on your cancer, previous treatments, general health and other medicines. Discuss the benefits and risks with your specialist so you can understand which treatment is most suitable for you. Never start, stop or switch medicines without medical advice.
If you are considering prostate cancer treatment in London and would like specialist advice, you can contact our team at Prostate Clinic London to discuss your treatment options and arrange a consultation tailored to your individual needs.
References:
- Khalaf, D.J. et al. (2019) ‘Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 crossover trial’, The Lancet Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/31727538/
- Mori, K. et al. (2020) ‘Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis’, Prostate Cancer and Prostatic Diseases. Available at: https://pubmed.ncbi.nlm.nih.gov/32152435/
- Matsukawa, A. et al. (2025) ‘Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis’, Prostate Cancer and Prostatic Diseases. Available at: https://pubmed.ncbi.nlm.nih.gov/39237679/
- Valikovics, A.K. et al. (2026) ‘Efficacy and safety differences between abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of real-world studies’, Targeted Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/42371314/
- Electronic Medicines Compendium (2026) Abiraterone 500 mg film-coated tablets: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15402/smpc
- Electronic Medicines Compendium (2026) Enzalutamide Astellas 40 mg film-coated tablets: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/10318/smpc
- NHS England (2026) Abiraterone acetate and prednisolone for high-risk, hormone-sensitive, non-metastatic prostate cancer (adults): Clinical commissioning policy. Available at: https://www.england.nhs.uk/publication/abiraterone-acetate-and-prednisolone-for-high-risk-hormone-sensitive-non-metastatic-prostate-cancer-adults/